| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453170 |
| ISSN: | 0034-8376 |
| Autores: | Córdova Ramírez, Alejandra C1 Sánchez Valledor, Luisa F1 Colótero, Gerardo4 Rivera Alvarez, Montserrat1 Elías de la Cruz, Gilberto D1 Murrieta Alvarez, Montserrat1 Cantero Fortiz, Yahveth1 León Peña, Andrés1 Olivares Gazca, Juan C1 Ruiz Delgado, Guillermo J1 Ruiz Argües, Guillermo J1 |
| Instituciones: | 1Centro de Hematología y Medicina Interna de Puebla, Puebla. México 2Mayo Clinic, Jacksonville, Florida. Estados Unidos de América |
| Año: | 2021 |
| Periodo: | Mar-Abr |
| Volumen: | 73 |
| Número: | 2 |
| Paginación: | 94-99 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Background: The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México. Objective and Methods: This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified. Results: There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006). Conclusion: Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy |
| Disciplinas: | Medicina |
| Palabras clave: | Hematología, Oncología, Células del manto, Linfoma no Hodgkin, Variabilidad racial, Pronóstico |
| Keyword: | Hematology, Oncology, Mantle cell, Non-Hodgkin lymphoma, Ratial variation, Prognosis |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
